We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

5 hedge funds and large institutions have $907K invested in XTL Biopharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 4 → 5 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

31% less capital invested

Capital invested by funds: $1.31M → $907K (-$407K)

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$76.5K
2
Morgan Stanley
Morgan Stanley
New York
+$2.17K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$271K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$714K -$271K -12,495 -25%
Invesco
2
Invesco
Georgia
$123K – – –
Citadel Advisors
3
Citadel Advisors
Florida
$67K +$76.5K +3,530 New
Morgan Stanley
4
Morgan Stanley
New York
$2K +$2.17K +100 +333%
TRCT
5
Tower Research Capital (TRC)
New York
$1K – – –

XTLB Hedge Fund Activity: Q3 2016 in Review

5 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q3 2016, worth a combined $907K — down 31% from $1.31M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $76.5K. The largest seller was Sabby Management, cutting an estimated $271K.

  • 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q3 2016, up from 4 in Q2 2016.
  • Funds reported $907K of XTL Biopharmaceuticals stock for Q3 2016, down 31% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q3 2016 and 0 closed out, a net change of +1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q3 2016 was Citadel Advisors, an estimated $76.5K added.
  • The largest XTL Biopharmaceuticals seller in Q3 2016 was Sabby Management, an estimated $271K sold.

Based on aggregated 13F filings for Q3 2016.